Conference Day 1
A PROMISING FORWARD LOOK INTO THE MICROBIOME FIELD
8:20 am Chair’s Opening Remarks
8:30 am Microbiome Fireside Leaders Chat: A Forward Look
Synopsis
- How do you perceive the overall role of the microbiome? How has this changed in the past 12 months?
- What is missing from the microbiome area of drug discovery?
- What are the gaps that both investors and drug developers must see, that we need to bring from other parts of biotech R&D?
- How is a microbiome-therapeutic going to complete against other drugs in the field?
9:30 am Overcoming Challenges Associated with Performing Bioburden & Other Purity Tests for Microbiome Based Therapeutics
Synopsis
- Microbiome therapeutic products are changing the future of medicine as we know it. Bioburden and other tests for purity of therapeutic products are required by regulatory agencies in order to ensure the safety of patients
- However, these tests often have challenges due to the fact that most microbiome based therapeutics are composed of live biotherapeutic organisms. This presentation will dive into the microbial tests for purity that are commonly conducted for microbiome based therapeutics, the common issues observed during execution of these tests and how to overcome these challenges
10:00 am New Frontiers in Microbiome Therapeutics: Inhaled Live Biotherapeutics for Chronic Lung Diseases
Synopsis
Download the full event guide for more information.
10:30 am Investing in the Analytical Methods & Facilities for the Future of Live Biotherapeutic Products
Synopsis
- As an increasing number of Live Biotherapeutic Products move through clinical trials to commercialization, there is a growing need for more advanced analytical methods to characterize drug substance and drug product, establish CQAs, and ensure process control
- Facility design is instrumental to product purity and quality and contributes greatly to a smooth regulatory approval
- Investing in analytics and facility design to help bring therapies to patients
11:00 am Morning Break, Refreshments & Structured Speed Networking
11:26 am
TRACK A:
UNDERSTANDING MICROBIOME FUNCTIONALITY TO UNCOVER PRECLINICAL DEVELOPMENT
UNDERSTANDING MICROBIOME FUNCTIONALITY TO UNCOVER PRECLINICAL DEVELOPMENT
Learn the approaches & platforms being harnessed to identify new therapeutic targets to see how you can incorporate the latest scientific findings into your own product pipeline
11:30 am How Comfortable are you with your Preclinical Design?
Synopsis
- What is still missing to fully encapsulate microbiome functionality?
- Is preclinical development positioned correctly in order to carve the way for clinical development?
- Insights into the use of microbiome metrics to inform clinical development
12:00 pm AstraZeneca & the Lung Microbiome
Synopsis
- The role of the lung microbiome in chronic lung disease
- Can we harness the microbiome for target discovery?
- Case study in bridging animal models and experimental medicine data for target discovery
12:30 pm Heterogeneity in On- and Off-target Statin Responses Explained by Variation in the Human gut Microbiome
Synopsis
- Statins are the most prescribed drug in the developed world, with hundreds of millions of users worldwide
- Prior work has shown that gut commensal bacteria can metabolize many drugs in vitro, including statins
- Genomic variation is known to modulate the efficacy of statins, but little is known about how the gut microbiome might modulate in vivo host responses
- We show how variation in the gut microbiome can explain variation in statin efficacy and in statin side effects, and this variation is orthogonal to the variation explained by the dominant human genetic loci associated with statin responses
TRACK B:
GETTING INTO THE CLINIC TO CLINICAL CASE STUDIES
GETTING INTO THE CLINIC TO CLINICAL CASE STUDIES
Listen to the exciting clinical case studies surrounding the microbiome, as well as advice on clinical assessment, safety & getting your program into the clinic
11:30 am Improve Your Clinical Trial Design, Safety and Assessment
Synopsis
Download the full event guide for more information.
12:00 pm Modulation Of Microbiome Bacterial Targets to Treat Human Diseases, A Case Study
Synopsis
- Bacterial target to disease link
- Bacterial target druggability assessment
- Challenges in microbiome drug discover
12:30 pm Potentials for New Drugs or Clinical Trials Validation using Circulating Microbiome
Synopsis
- In the recent past, Microbiome tools and sciences have exploded. But this remains mostly focused on gut, oral or skin microbiome
- It is starting to be well established that tissue and plasma have an existing microbiome as well that should be mined for novel applications
- We will discuss potential implications of this novel insight for drug development
TRACK C:
GMP MANUFACTURING, SCALE UP AND MORE
GMP MANUFACTURING, SCALE UP AND MORE
Hear from subject experts on the major challenges regarding manufacturing and scaling up of the microbiome products, & how to overcome these through the clinic in order to move your products closer to approval and commercialization
11:30 am Key Challenges in Process Development for LBP DS Manufacturing
Synopsis
- Animal component free culture media
- Determining the optimal harvest time
- Quantification of live bacteria
12:00 pm Creating a Metabolomics Pipeline for Investigating Microbiome-host Interactions
Synopsis
- Creation of a metabolomics pipeline for small molecule discovery
- In vitro and in vivo applications of this pipeline on discovering metabolic patterns and manipulating gut microbial metabolites in the mouse models
12:30 pm Manufacturing Strategies to Broadly Access Biological Breadth of the Microbiome
Synopsis
Download the full event guide for more information.
1:00 pm Lunch & Networking
2:00 pm Hear the Ever Evolving Research Surrounding New Indications in Pre-clinical Development at Siolta Therapeutics
Synopsis
Download the full event guide for more information.
2:30 pm Microbiome Considerations in Preclinical Animal Modeling
Synopsis
- Introduction on the role of the microbiome in various human disease states
- Discussion of strategies for assessing microbiome effects in disease models
- Examples of microbiome influence in disease modeling
3:00 pm What can we Learn From FMT Murine Models?
Synopsis
- Multiple variables affect FMT murine models, including sex and cage effect, and controlling these factors may lead to more consistent results
- Post human to mouse FMT, a subset of human bacteria can establish in mice. The abundance after FMT correlated with abundance in the inocula with more variability in low abundance OTUs
- Three Clostridia species correlated with tumor response in R-FMT mice treated with anti-PD-L1 antibody, along with Multiple T and NK cell immune pathways
3:30 pm Understand How Gelesis’ can Help Your Pipeline
Synopsis
- Introduce Gelesis’ oral superabsorbent hydrogels (OSH) and their potential use in the treatment of metabolic disorders
- Discuss of how OSH treatment drives compositional changes to the intestinal microbiota in pre-clinical mouse models of diet-induced obesity
- Provide a brief overview of the human clinical data we are generating to confirm our pre-clinical observations
2:00 pm Uncover How the Gut-brain Axis is Proving to Successfully Provide Clinical Progress
Synopsis
Download the full event guide for more information.
2:30 pm Incorporation of Metabolomics in a Multi-Omics Microbiome Analysis – A tool for Clinical Research
Synopsis
- Microbiome research around the mechanism leading to health and disease conditions has increased drastically
- Incorporation of different *omics* approaches is necessary for such research
- Incorporation of Metabolomics as a microbiome analysis tool has become more common
- Since the methods vary widely between different studies and labs, the results are often incomparable
- Standardization is crucial for translating the scientific finding into clinical practice
3:00 pm Learn Insights Into the Link Between GI Tumors & the Microbiome
Synopsis
- Microbiome is associated with response to ICI therapy in GI tumor patients
- Cross reactive antigens (CRAgs) between microbiota and tumor are associated with patient response to ICI therapy
- CRAgs quality, such as overlap with virulence factors, are associated with patient response
3:30 pm Development of a Synthetic Biotic for the Treatment of Phenylketonuria
Synopsis
- Phenylketonuria is a rare inherited disorder of Phenylalanine metabolism, with significant risk of neurocognitive impairment and high unmet need
- Our team at Synlogic has developed SYNB168, an engineered Synthetic Biotic to consume Phe in the GI tract that demonstrated fasting plasma Phe lowering in patients with PKU
- The SYNB1618 clinical data validate Synlogic’s mathematical modeling approach for the development of Synthetic Biotic medicines
2:00 pm PANEL: Uncover How Manufacturing & Formulation Along Your Pipeline can be Improved
Synopsis
- How do we make sure we are maintaining a viable product when scaling up manufacturing?
- Anaerobic vs aerobic microbes – What are the main challenges faced when working with each?
- How can we consistently show that we are able to produce the same product and prevent result fluctuations?
- How do we keep manufacturing at scale cost efficient?
- What challenges do we face delivering products one they are at a large, commercial scale?
2:30 pm Development of Microbiome Drug Products
Synopsis
Download the full event guide for more information.
3:00 pm Development of a Novel Live Biotherapeutic Product for the Prevention of CDI
Synopsis
Download the full event guide for more information.
3:30 pm Building a World-Class Microbial & Viral Vector Manufacturing Facility
Synopsis
- Overview of Locus Biosciences business and history
- Rationale for internalizing manufacturing and designing capabilties
- Bacteriophage cocktail production for clinical trials
4:00 pm Afternoon Break & Networking
4:30 pm Leveraging Experience & Expertise to Support the Development & Manufacturing of Microbiome Therapeutic Products
Synopsis
- Utilization of single use equipment in the LBP process flow
- Novel dosage forms
- Innovative product delivery platforms
- Microbiome derived protein products
4:40 pm Targeting the Microbiome with Synthetic Glycans for Improved Disease Outcomes
Synopsis
- Synthetic glycans driving microbiome composition and functional output
- How recent insights in mode of action enable innovation
- Clinical study with KB295 in ulcerative colitis
4:30 pm Paving the Way of Blood & Tissue Microbiome Research
Synopsis
Download the full event guide for more information.
4:40 pm ONCOBAX®-AK, a game-changer Live Biotherapeutic Product for anticancer immunotherapy
Synopsis
- The composition of the gut microbiota influences the effectiveness of anticancer immunotherapy
- EverImmune has developed Oncobax®-AK, a breakthrough microbiome technology as oral adjuvant for anticancer immunotherapy in
- NSCLC and RCC patients treated with ICIs, that will enter into clinics 2nd quarter 2022.
- EverImmune has developed companion diagnosis tools to identify patients amenable to Oncobax®-AK
4:30 pm Scale Up & GMP Manufacture of LBPs
Synopsis
- Consideration for technology transfer and development of LBPs prior to GMP
- Assessing the scale-up considerations and challenges associated with LBPs in early clinical trial material
- Outlining viability and yield considerations throughout the manufacturing process to bulk drug product
4:40 pm Translating Microbiome Data For Efficacious Product Development
Synopsis
- Key product developments insights to be had from analyzing microbiome data
- BIOHM has had success in translating raw microbiome insights into commercialized products
- Significant opportunities around AI applications to microbiome data